Biogen (NASDAQ:BIIB) Stock Rating Upgraded by Zacks Research

Biogen (NASDAQ:BIIB) was upgraded by investment analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.

A number of other research firms also recently issued reports on BIIB. Mizuho lowered their target price on Biogen from $236.00 to $221.00 and set an “outperform” rating on the stock in a research report on Monday, June 15th. UBS Group upgraded Biogen from a “neutral” rating to a “buy” rating and raised their price target for the company from $185.00 to $225.00 in a research note on Wednesday, April 22nd. Wall Street Zen raised Biogen from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Needham & Company LLC upped their price objective on Biogen from $255.00 to $256.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. Finally, Barclays increased their price objective on Biogen from $185.00 to $200.00 and gave the company an “equal weight” rating in a report on Wednesday. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating, thirteen have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Biogen presently has a consensus rating of “Moderate Buy” and a consensus target price of $221.11.

Biogen Stock Performance

Shares of BIIB stock opened at $209.43 on Tuesday. The firm has a market cap of $30.92 billion, a PE ratio of 22.47 and a beta of 0.16. Biogen has a 12 month low of $124.56 and a 12 month high of $219.72. The company’s fifty day simple moving average is $200.68 and its 200-day simple moving average is $190.37. The company has a quick ratio of 2.41, a current ratio of 3.06 and a debt-to-equity ratio of 0.34.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.94 by $0.66. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The firm had revenue of $2.74 billion for the quarter, compared to analyst estimates of $2.46 billion. During the same period in the previous year, the business earned $5.47 EPS. The company’s revenue was up 3.4% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. Equities research analysts expect that Biogen will post 11.28 EPS for the current fiscal year.

Hedge Funds Weigh In On Biogen

A number of institutional investors have recently bought and sold shares of BIIB. Reflection Asset Management bought a new stake in Biogen in the fourth quarter valued at approximately $25,000. WPG Advisers LLC boosted its stake in shares of Biogen by 417.9% during the 4th quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock worth $26,000 after acquiring an additional 117 shares during the period. First Horizon Corp bought a new position in shares of Biogen during the 4th quarter worth approximately $30,000. WFA of San Diego LLC acquired a new position in shares of Biogen during the 2nd quarter worth approximately $32,000. Finally, Root Financial Partners LLC increased its holdings in shares of Biogen by 198.4% during the 4th quarter. Root Financial Partners LLC now owns 185 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 123 shares during the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Biogen News Roundup

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen reported second-quarter revenue of approximately $2.74 billion, up 3.4% year over year and above the roughly $2.46 billion consensus estimate. Adjusted EPS of $3.60 also exceeded expectations, supporting the positive market reaction. Reuters article
• Positive Sentiment: The Growth Portfolio generated $1.06 billion in revenue, up 24% year over year and ahead of the legacy multiple sclerosis portfolio. SKYCLARYS, ZURZUVAE, and products acquired through the Apellis transaction—including SYFOVRE and EMPAVELI—provided important growth contributions. The Pharma Letter article
• Positive Sentiment: Biogen raised its full-year 2026 revenue outlook to mid-single-digit growth versus 2025, reflecting momentum in newer drugs and the Apellis acquisition. Analysts also highlighted pipeline progress, including encouraging early Alzheimer’s data for diranersen. Seeking Alpha article
• Neutral Sentiment: Leqembi sales continued to grow, reaching 29.3 billion yen globally in the quarter, but narrowly missed some expectations. The Alzheimer’s drug remains strategically important, although its near-term contribution is being weighed against commercialization costs and competition. Leqembi sales article
• Negative Sentiment: GAAP net income fell sharply to $97.5 million from $634.8 million a year earlier, while reported EPS declined to $0.66 from $5.47. Biogen’s updated 2026 non-GAAP EPS guidance of $12 to $13 is below the prior consensus estimate of $13.45, tempering the otherwise strong earnings reaction. The Wall Street Journal article
• Negative Sentiment: Legacy multiple sclerosis products remained under pressure, highlighting Biogen’s continuing dependence on successful execution of its newer rare-disease, Alzheimer’s, and acquired-product portfolio.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.